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Abstract
Background—Cognitive impairment is a key feature of psychiatric illness, making cognition
an important tool for exploring of the genetics of illness risk. It remains unclear which measures
should be prioritized in pleiotropy-guided research. Here, we generate profiles of genetic overlap
between psychotic and affective disorders and cognitive measures in Caucasian and Hispanic
groups.

Author Manuscript

Methods—Data were from four samples of extended pedigrees (N = 3046). Coefficient of
relationship analyses were used to estimate genetic overlap between illness risk and cognitive
ability. Results were meta-analyzed.
Findings—Psychosis was characterized by cognitive impairments on all measures with a
generalized profile of genetic overlap. General cognitive ability shared greatest genetic overlap
with psychosis risk (average Endophenotype Ranking Value (ERV) across samples from a random
effects meta-analysis = 0.32) followed by Verbal Memory (ERV = 0.24), Executive Function (ERV
= 0.22), and Working Memory (ERV = 0.21). For bipolar disorder, there was genetic overlap
with Processing Speed (ERV = 0.05) and Verbal Memory (ERV = 0.11), but these were confined
to select samples. Major depression was characterized by enhanced Working and Face Memory
performance, as reflected in significant genetic overlap in two samples.

Author Manuscript

Interpretation—There is substantial genetic overlap between risk for psychosis and a range of
cognitive abilities (including general intelligence). Most of these effects are largely stable across
of ascertainment strategy and ethnicity. Genetic overlap between affective disorders and cognition,
on the other hand, tend to be specific to ascertainment strategy, ethnicity, and cognitive test battery.
Keywords
cognition; genetic epidemiology; bipolar disorder; major depressive disorder; psychotic disorders;
family-based genetics
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Author Manuscript

Genomic variation substantially impacts risk for developing psychiatric illnesses, with
heritability (h2) estimates in the range of 0.4–0.8 (1). Recently, large-scale consortia have
made tremendous strides to assemble large case-control samples (2). However, most of
the genetic architecture of psychiatric disorders remains unclear (3). A complementary
approach, which may provide additional insight, is to identify behaviors that overlap
genetically with risk for psychiatric illness, which may also provide a rubric for
prioritization of measures to be included in future research.
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Cognitive abilities, which are heritable, have been frequently investigated in terms of
their genetic overlap with psychiatric illness (4). However, important questions remain
unanswered regarding these relationships. First, why do estimates of genetic overlap
between cognitive abilities and psychiatric illness vary so considerably between studies?
Prior research on this topic has mostly been conducted using family studies—either
classic twin designs or extended pedigree designs—or by leveraging single-nucleotide
polymorphism (SNP) data in unrelated individuals. Genetic correlations estimated via twin
designs tend to be high (5), leading some to argue that they may be overestimates (6).
SNP-based methods were introduced partly due to the perceived drawbacks of twin designs
and to squeeze more signal from genome-wide association (GWA) data (7). However,
important limitations of the SNP-based approach are that SNPs do not capture the full range
of genetic variation (3) and that most approaches do not adequately account for linkage
disequilibrium and variation in allele frequency (8). Pedigree designs may be well placed
to provide a definitive answer to the degree of genetic overlap between risk for psychiatric
illness and cognitive ability because (1) there is less confounding of genetic and shared
environmental effects in pedigree than twin designs; (2) pedigree designs do not rely on
population-level information regarding LD and allele frequency; and (3) pedigree designs
are robust to population stratification (9).

Author Manuscript

A second question pertains to the use of broad composite measures of cognitive ability
rather than specific domains or measures. General cognitive ability, or g, is a robust
phenotype (10–12). However, g is a distillate of what is common across cognitive tests and
is insensitive to specific sources of cognitive impairment. This is unlikely to be a problem
for studies of psychotic disorders, which are associated with general cognitive impairments
(13), but may be problematic for studies of affective disorders, since their cognitive profile
is characterized by selective impairments (14). Selection of correct cognitive phenotypes is
critical for the detection and interpretation of genetic overlap between psychiatric illnesses
and cognition.
A third issue is that prior research efforts are heavily skewed toward psychosis. This is
partly because cognitive impairment is considered a core feature of psychosis (13). While
impairments are observed for major depression (MD) (15) and bipolar disorder (16), they are
less severe. Moreover, gene discovery for affective disorders has lagged behind psychosis.
Genome-wide significant hits have recently emerged in large samples for affective disorders,
the phenotypic specificity in such large samples tends to be low (17). Extended designs
cannot compete with GWA consortia in terms of sample size; however, it is likely that
carefully conducted and ascertained pedigree studies will have more reliable and detailed
phenotypes.

Author Manuscript

In the present study, we meta-analyzed four large extended pedigree samples (total
N = 3046) to examine the genetic overlap between risk for psychiatric illness and
cognitive ability. We generated profiles of genetic overlap, which provide rapid and
clear understanding of the direction and magnitude of pleiotropy between multiple
cognitive domains and psychiatric illnesses. The included samples span multiple disorders,
international sites, ethnicities, and ascertainment strategies. Using this approach, we
attempted to answer the following questions: (1) Are profiles of genetic overlap similar
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within disorders across sites (and by extension, ethnicities and ascertainment strategies)? (2)
Are profiles similar across disorders within/across sites? (3) Are profiles for psychotic and
affective disorders similarly generalized, or are there stronger overlaps for specific measures
or domains in the latter? The answers provide guidance for future work aiming to more
deeply phenotype cognition and psychiatric disorders.

Methods and Materials
Samples

Author Manuscript

Data comprised four samples (Costa Rican, Mexican American, Pennsylvanian and Western
Australian; see Supplemental Materials and Tables S1–4) with cognitive and genotype data
in healthy individuals and individuals with psychotic and affective disorders. Two were of
Hispanic ancestry (Costa Rican and Mexican American) and two were European Caucasian
(Pennsylvanian and Western Australian). These samples represent the subset of the Whole
Genome Sequencing in Psychiatric Disorders (WGSPD) consortium (9) with cognitive data.
The total sample size was 3046, including 191, 96, and 771 patients with psychosis, BP, and
MD, respectively. Broad diagnostic categories were used in each instance (e.g. psychosis
refers to any individual with a schizophrenia, schizoaffective, BP or MD with psychosis
diagnosis, and BP refers to any individual with a BP I or BP II diagnosis without psychosis;
Tables S5/6).
Cognitive Assessments
Cognitive tests varied across samples, but the breadth of assessments permitted evaluation
of genetic overlap between measures spanning multiple cognitive domains, plus g (see
Supplemental Materials), with risk for psychiatric illness (Table S7).

Author Manuscript

Phenotypic Effect of Diagnosis on Cognition
Group differences for each diagnosis were calculated for all cognitive measures in each site
using standardized mean differences (SMDs) and the absolute values were meta-analyzed
using the rma function from the metaphor (18) package in R (19).
Heritability Analysis
Univariate variance components analyses of cognitive measures (including g) were
performed in SOLAR using genomic relatedness matrices that were empirically estimated
(see Supplemental Materials) (20). Age, age2, sex and their interactions were included as
covariates.

Author Manuscript

Coefficient-of-Relatedness Analysis
In samples ascertained for a particular illness it is usually necessary to apply a correction to
avoid biasing estimation of h2. This was not necessary here because we did not explicitly
model h2 of illness risk but instead estimated h2 of each cognitive measure and included a
coefficient of relatedness (CoR) as a covariate. CoR analysis leverages the many coefficients
of relationship that exist between individuals in extended pedigrees to explore the genetic
relationship between a phenotype and a disease when the disease is not sufficiently common
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in the sample to estimate its heritability (see Supplemental Materials). Here, CoR analysis
was applied using cognitive measures as phenotypes and psychosis, BP, and MD as diseases.
Age, age2, sex and their interactions were included as covariates. False discovery rate (FDR)
was set at 5% (21).
Profiles of Genetic Overlap
The regression coefficient corresponding to the CoR, denoted by β, can be converted to
a mean-based endophenotype ranking value (ERV). ERV is an index of genetic overlap
that varies between 0 and 1, higher values indicate that the endophenotype and the illness
have greater genetic overlap (22). First, we graphed β estimates from the above analyses,
grouping by disorder across samples. Second, we converted βs to ERVs and pooled them
using the metacor function from the meta package in R (23) (see Supplemental Material).
Finally, we ranked cognitive measures by ERV within site.

Author Manuscript

Results
Sample Description
Demographics, clinical characteristics, and numbers of kinship pairings (>0.01) available for
each diagnosis, are summarized in Tables S5 and S6. Across all samples, mean age = 42.57
years (sd = 16.43) and 54.17% were female.
Phenotypic Effect of Diagnosis on Cognition
Effect sizes for differences in performance on cognitive measures between cases and
controls are shown in Tables S8–10, which are ordered by ERV.

Author Manuscript

For psychosis (Table S8), cognitive impairments were wide ranging (range of absolute
Standardized Mean Difference (SMD) = 0.15-1.20). g was ranked in the top-three for all
sites, and top in the Pennsylvanian and Western Australian sites. In the Mexican American
and Costa Rican samples, the greatest difference for psychosis were the Verbal Memory
measure CVLT and Executive Function measure PCET respectively. Meta-analysis of these
effects (Figure S1) for psychosis indicated that the largest difference observed across sites
was for g (SMD = 1.02) with consistent effects observable for all measures with the
exception of Executive Function, which was subject to heterogeneity.

Author Manuscript

For BP (Table S9) and MD (Table S10), a handful of cognitive impairments and
improvements were observed (Figures S2 and S3 show meta-analyses). For BP, the range
of absolute SMDs = 0-1.18. In the Pennsylvanian and Costa Rican samples, the greatest
impairments for BP were for the Verbal Memory measure the CVLT. The following
improvements were observed for BP cases: Digit Span Backward in the Mexican American
sample; Digit Span Forward in the Costa Rican sample; and Emotion Recognition in the
Pennsylvanian sample. The phenotypic results for psychosis and BP, in particular in the
Western Australian sample, should be interpreted with the caveat that they are based on a
small number of cases. These results have been included for the sake of completeness and
consistency across disorders.
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For MD, small to moderate impairments were observed in most samples (range of absolute
SMD = 0.10-0.62). In the Mexican American sample, the largest impairment was for the
Digit Span Forward. In the Costa Rican sample, the largest difference was for Facial
Memory, where cases outperformed controls. In the Pennsylvanian and Western Australian
samples, MD cases exhibited higher scores than controls on all tasks. For the Pennsylvanian
sample, the greatest difference was on Facial Memory followed by g. For the Western
Australian sample, the greatest difference was for Verbal Memory followed by g (see
Supplemental Materials for meta-analyses).
Heritability of Cognitive Measures
Heritability estimates for all tests were small to moderate (Figure S4). Tests that were
measured across different sites tended to demonstrate similar strength of heritability
estimate, suggesting that h2 is similar across ethnicities and ascertainment.

Author Manuscript

Coefficient of Relatedness Analysis: Generating Profiles of Genetic Overlap

Author Manuscript

Significant genetic overlaps, indexed by the ERV, were observed between most cognitive
abilities and psychosis risk across sites (Figure 1). Measures were ranked by ERV in each
site (Table S8). In terms of similarities between sites (and, by extension, ethnicities and
ascertainment strategies), the direction of ERV effects were the same irrespective of site,
indicating that genetic liability was associated with worse performance on all measures.
In all sites, g was ranked in the top three. A number of those measures that survived
FDR correction (Figure 2) were present in at least two sites, including the: the Digit Span
Forward; Executive Function measure the PCET; CVLT and RAVLT; Emotion Recognition;
Attention measure the CPT. Thus, Verbal Memory and Working Memory ranked highly in
samples of differing ethnicity and ascertainment strategies. Table 1 shows the results of a
meta-analysis of ERV estimates grouped by domain and ranked by magnitude of effect.
The meta-analysis underscored that some domains demonstrated greater genetic overlap
with psychosis risk than others (e.g. g and Verbal Memory). The Q-statistic, an index of
heterogeneity of observed effects, is informative here, since a significant Q-value indicates
that domains were affected differently in different sites. For example, Verbal Memory is
ranked second but variation in effect size attributable to heterogeneity was high indicating
that similar effects were not observed in all sites. Consistent effects (i.e. with minimal
heterogeneity) were observed for g, Working Memory and Emotion Identification.

Author Manuscript

Compared to psychosis, neither risk for BP nor MD demonstrated the same wide-ranging
profile genetic overlap with cognition but some specific associations were observed.
For BP (Table S9; Figure 3) performance on the: Semantic Fluency task demonstrated
genetic overlap in the Costa Rican and Mexican American samples; the Facial Memory
Delayed task in the Costa Rican sample; and on Verbal Memory (CVLT/RAVLT) tasks
in the Mexican American, Pennsylvanian and Western Australian samples. In most
instances, increased genetic proximity to an individual with BP resulted in a decrement
in performance. However, no genetic overlap between BP and any cognitive measure were
significant after FDR correction (Figure 4).
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Risk for MD (Table S10) demonstrated genetic overlap with multiple cognitive measures
(Figure 3), a number of which withstood FDR correction (Figure 5), which were specific
to particular samples. These included the Facial Memory measures in the Costa Rican and
Pennsylvanian samples, where increased genetic proximity to MD improved performance.
The same direction of relations was observed for g in the Pennsylvanian and Western
Australian samples, Spatial Memory (SCAP), and Attention (CPT) in the Pennsylvanian
sample, and Verbal Memory (RAVLT) in the Western Australian sample.
Effect of Sex on Genetic Overlap Between Depression and Cognition

Author Manuscript

At the suggestion of one of the reviewers we explored whether the genetic overlap observed
between MD and cognition might vary by sex. We tested the significance of an interaction
term between genetic risk for MD (indexed by the CoR utilized in previous analysis) and
sex in the univariate polygenic model of each cognitive measure. This analysis was restricted
to those measures with ERVs withstanding FDR correction (Figure 5). The supplemental
material contains the results of these analysis (Table S11). Two of the measures, Facial
Memory Delayed (β = −0.65, p = 0.02) in the Costa Rican sample and Attention measure the
CPT (β = −0.47, p = 0.04) in the Pennsylvanian sample, demonstrated nominally significant
interactions between sex and genetic liability for MD indexed by a CoR, indicating that
the relationship between genetic liability for MD and performance on these measures is
somewhat stronger in men than in women.

Discussion

Author Manuscript

We report profiles of genetic overlap, indexed by the ERV, between cognitive ability
spanning multiple domains and risk for psychiatric illness in four extended-pedigree datasets
that span multiple ascertainment strategies, psychiatric illnesses, and ethnicities. This is a
comprehensive study of the genetic link between cognition and risk for psychiatric illness in
related individuals. Results provide insight at the epidemiological level (i.e. the phenotypic
relationship) and are mechanistically informative (i.e. the genetic relationship). Not all
findings are novel, however the present manuscript offers a holistic view, allowing a direct
comparison of findings across research designs and ethnicities.

Author Manuscript

While GWA studies have identified numerous genomic loci that contribute to risk for
psychotic and affective disorders (24) much of their genetic architectures remain unclear
(3). Cognitive endophenotypes have the potential to provide increased understanding of the
genetic determinants of the psychiatric illnesses (25, 26). In future research, prioritization
of which cognitive measures to include is of utmost importance. Much is known regarding
the phenotypic overlap between certain disorders and cognitive measures, however the
following question remains unanswered: which measures are most likely to yield further
genomic insight into psychiatric illness? This question is particularly important given that
efficacious phenotyping is a practical requirement for the type of large-scale data collection
necessary for gene identification (27). Despite the established importance of pleiotropy in
improving understanding of disease pathogenesis, not to mention its potential for genetic
risk profiling, few studies have systematically investigated the extent of pleiotropy between
psychiatric disease risk and other complex traits, including cognition (28, 29). The present
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study attempts to provide a rubric for future studies by creating profiles of genetic overlap
between psychotic and affective disorder risk and a wide range of cognitive measures.
In the present study univariate h2 estimates of cognitive ability are in line with what has
previously been reported in the literature. Generally, h2estimates for g are moderate to high,
varying between 40-.80 (30), in the present study estimates for g were between 0.46-0.67. In
the literature the h2 of individual cognitive measures vary from low to high, depending on
the measure in question, this is also what we observed in the present study (Table 2).

Author Manuscript

Our observed pattern of cognitive impairments in psychosis patients is consistent with
previous research (13), with broad ranging decrements in performance across domains.
In each site, increased genetic liability for psychosis was associated with lower cognitive
performance. While the precise ordering of measures varied between samples, there were
similarities, suggesting that some tests were more robustly associated with psychosis
liability than others. g was in the top-three of measures ranked by degree of genetic overlap
(as indexed by the ERV). Also, the genetic overlap for Verbal Memory (indexed via the
CVLT and the RAVLT) and psychosis liability survived multiple-testing correction in three
of the four samples. One of these samples (Costa Rican, of Hispanic ancestry) had a focus
on BP in terms of ascertainment strategy, while the other two (Pennsylvanian and Western
Australian, of European ancestry) primarily recruited schizophrenia patients. Other overlaps
that replicated across sites included Working Memory measures (Digit Span Forward, Digit
Span Backward and Letter Number Sequencing) and the Executive Function measure PCET;
similar to the effects observed for Verbal Memory, these effects were observed irrespective
of ancestry and psychosis ascertainment.

Author Manuscript
Author Manuscript

While the genetic overlap between psychosis risk and cognitive ability is well established,
the replication of genetic overlap between psychosis risk and specific cognitive tests across
multiple samples of extended pedigrees is novel. Cognitive impairment is a particularly
pernicious aspect of psychosis, contributing directly to the social isolation and functional
impairments (13); unfortunately, there are no approved treatments for cognitive impairment
in psychosis. Isolating the mechanisms by which cognitive impairment arises in psychosis
will be important if treatments are to be identified. Our findings highlight that researchers
wishing to utilize cognition as an enhancer of genetic signal for psychosis risk g is
best. However, in a situation where brevity of assessment is key then a focus on some
combination of Verbal and Working Memory and Executive Function is key. Pleiotropic
discoveries such as this can help inform research that aims to identify shared biological
pathways and prioritize probable causal relationships (31). It was surprising that Processing
Speed measures (e.g. the Digit Symbol Substitution Task; DSST) did not demonstrate
greater genetic overlap with psychosis risk. Numerous meta-analytic studies suggest that
processing speed is the single largest cognitive impairment in schizophrenia (32). It is
possible that, in the present sample, differences at the phenotypic level between cases
and controls on processing-speed performance and psychosis risk were not influenced by
the same genetic influences, but rather are influenced by shared environmental or state
dependent factors. At the very least, the results of the present study suggest that measures of
processing speed might not take precedence over other more highly ranked domains and/or
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measures in genetic-pleiotropy informed research in the future (33). Importantly, this is not
to say that processing speed might not be informative from a clinical standpoint.

Author Manuscript

Differences in genetic overlap profiles between psychotic and affective disorders might
be considered strange given than numerous studies point to overlap in the genetic loci
that predispose risk for these disorders (34), the reasoning being that if the genetics of
the disorders are similar then the ordering of genetic overlap between cognitive abilities
should also be similar. However, differing profiles make sense. First, the genetic correlation
between liabilities for psychotic and affective disorders is partial (1, 35), allowing for
differences in genetic overlap profiles in cognition. Second, these disorders have a high
degree of clinical overlap (36), and any genetic overlap might pertain to this rather than
similarities in cognitive impairments per se. Third, specific SNPs that influence cognitive
ability in both, for example, bipolar and psychosis, might still be expressed at the phenotypic
level in a differing manner (37). Differential phenotypic expression might be tied to
molecular mechanisms (e.g. epistasis of non-overlapping genetic influences) or the ways
in which such alterations fit within the clinical picture.

Author Manuscript
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An unexpected finding was that MD cases demonstrated elevated performance on some
measures and that those differences appeared to be genetically mediated. In two sites
(Costa Rican and Pennsylvanian), performance was better in MD cases than in controls
on Facial Memory tasks, effects that were matched by positive and significant genetic
overlaps. The Facial Memory task presents participants with images of faces with neutral
affect, followed by a testing period where the original faces are presented alongside foils,
and participants indicate which faces they recognize (38). Facial memory is considered a
neurally and cognitively dissociable trait from general cognitive ability (39). The brain has
highly specialized regions and networks that are preferentially activated by faces (40, 41). It
has been postulated that these neural underpinnings, which support this specialized ability,
are specifically evolved in humans for the purpose of face recognition because it is such a
crucial skill for human social interaction (42). We are not the first to find that depressed
mood is associated with enhanced face-memory ability. Healthy participants that are induced
to feel sad outperform those that feel happy or neutral on Facial Memory tasks (43). One
explanation of this apparent advantage in MD cases for Facial Memory is that depressed
mood can give rise to attentional biases that benefit the processing of negative stimuli i.e.
a mood-congruency bias (44–46). The stimuli in the Face Memory task used in the present
study are neutral, which can be interpreted negatively (47). However, a mood-congruency
bias is unlikely to explain our results. The presence of a positive genetic overlap in addition
to a phenotypic effect strongly suggests that enhanced performance of depressed individuals
on the Facial Memory tasks is driven by trait- and not state-dependent mechanisms; that is,
a subset of the biological mechanisms which predispose MD risk also mediate performance
on these measures. The present work suggests that a circumspect approach to cognitive
test selection may be advantageous for MD research, where Facial Memory is a potential
endophenotype. Interestingly, despite the increased liability of MD in women (48), and the
apparent face memory advantage conferred by being female (49), the link between increased
genetic liability for MD and enhanced performance on the Facial Memory task was more
pronounced in men in the Costa Rican sample. Thus, in some populations Facial Memory
may be a better allied phenotype for MD in men than in women. The present study is not
Biol Psychiatry. Author manuscript; available in PMC 2022 September 15.
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designed to test such hypotheses but generates testable hypotheses pertaining to this issue
for future work.

Author Manuscript

When interpreting the results of the present study, a number of limitations should be
considered. First, associations between cognition and, for example, psychosis risk may be
confounded by environmental factors (e.g. in the familial environment). Second, we were
required to rely on high-level diagnostic categories rather than being able to make inferences
based on symptom-level data that would have enabled the demarcation of subgroups of
disorders (including age of onset, illness severity and so on). There is growing evidence
that fine-grained diagnostic phenotyping in genetics research is crucial for reliability and
validity of reported associations (50). Third, this observational study is best described as
correlational and as such does not allow us to make causal inferences about the impact
of cognitive ability on risk of psychiatric illness. Fourth, the mechanistic insights provided
by the present study are limited by the lack of SNP-level information, which might be
used to reveal the involvement of specific genes and, by extension, molecular pathways in
psychiatric illness risk. Fifth, the phenotypic relationship (i.e. the SMDs between cases and
controls on cognitive performance) are, in some cases, based on a small number of cases.

Author Manuscript

Despite differences in each dataset’s design and population, we identified cognitive
measures that converge in terms of importance for particular psychiatric disorders from
a genetic perspective. Results are important given that efficacious phenotyping is a practical
requirement for the type of large-scale data collection necessary for gene identification.
Despite the established importance of pleiotropy (overlapping genetic influences on traits)
in improving understanding of disease pathogenesis, not to mention its potential for genetic
risk profiling, few studies have systematically investigated the extent of pleiotropy between
psychiatric disease risk and other complex traits, including cognition. The present study
attempts to provide a rubric for future studies by creating profiles of genetic overlap between
psychotic and affective disorder risk and a wide range of cognitive measures. Overall, the
present study provides future directions for etiological psychiatric research with a genetic
focus by highlighting which cognitive measures are most likely to prove fruitful when paired
with psychotic and affective illnesses.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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mERV β estimates for psychosis (CR = Costa Rican; MA = Mexican American; PA =
Pennsylvanian; WA = Western Australian).
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Figure 2.

Genetic overlap (or ERV) profiles for psychosis (*significant after multiple testing
correction; CR = Costa Rican; MA = Mexican American; PA = Pennsylvanian; WA =
Western Australian).
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Figure 3.

mERV β estimates for bipolar (BP) and major depressive (MD) disorders (CR = Costa
Rican; MA = Mexican American; PA = Pennsylvanian; WA = Western Australian).
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Figure 4.

Genetic overlap (or ERV) profiles for bipolar (BP) and major depressive (MD) disorders
(*significant after multiple testing correction; CR = Costa Rican; MA = Mexican American;
PA = Pennsylvanian; WA = Western Australian).
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Figure 5.

Genetic overlap (or ERV) profiles for major depressive disorder (*significant after multiple
testing correction; CR = Costa Rican; MA = Mexican American; PA = Pennsylvanian; WA =
Western Australian).
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Studies Estimating h2 of Cognitive Measures Included in the Present Study. Extended pedigree studies were
given preference to more closely resemble the research design of samples included in the present study.
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Software;
Algorithm

SOLAR

http://solar-eclipse-genetics.org/

RRID:009645

Software;
Algorithm

R version 4.0.3

http://www.r-project.org/

RRID:SCR_001905

Software;
Algorithm

metaphor pacakage in
R version 2.4.0

http://CRAN.R-project.org/
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package=metacor

RRID:SCR_019055
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